ICAM1 and neoplasm: Direct treatment with pyrazinib (P3) showed no effect on CD83, CD54, PD-L1, CD40 and HLA-DR expression in response to LPS, whereas both control and pyrazinib (P3) treated TCM significantly reduced the expression of CD83, suggesting that mediators secreted from the tumour microenvironment specifically exert an inhibitory effect on dendritic cell maturation.